推薦產品
3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole 2-(chloromethyl)-3-methylpyridinehydrochloride 1-(2-bromo-4-methylphenyl)ethanone 3-chloroisoquinoline-4-carbonitrile 5,8-dichloropyrido[3,2-d]pyridazine 2-bromomalononitrile 2-(4-(bromomethyl)phenyl)benzo[d]thiazole 1-(bromomethyl)-3-methoxy-2-nitrobenzene 6-bromo-1H-[1,2,3]triazolo[4,5-b]pyridine 4-iodo-2-((trimethylsilyloxy)methyl)thiazole 6-iodoimidazo[1,2-a]pyridine-3-carbonitrile 2-(4-chlorophenyl)-2-morpholinoacetonitrile 4-chloro-7H-pyrrolo[2,3-d]pyrimidine 4-chloroisothiazole 5-bromo-6-chloro-1H-indole 7-chloro-3H-imidazo[4,5-b]pyridine ethyl3-(4-formylphenyl)propanoate 2,3-dibromobenzaldehyde 1-(5H-chromeno[2,3-b]pyridin-7-yl)ethanone 5H-chromeno[2,3-b]pyridin-5-one 3-chloroisoquinoline-4-carbaldehyde (E)-2-(3-oxoprop-1-enyl)benzaldehyde methyl4-formyl-3-nitrobenzoate 5,6-dimethoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-one 1-methylbicyclo[4.1.0]heptan-3-one 3-nitro-4-(trifluoromethoxy)benzaldehyde 2-hydroxyquinoline-6-carbaldehyde 2-nitro-3-(trifluoromethyl)benzaldehyde 1-(2-fluoro-4-methoxyphenyl)propan-2-one tert-butyl3-fluoro-4-oxopiperidine-1-carboxylate tert-butyl3-oxopropylcarbamate 2,2-dimethylcyclohexanone 9H-carbazole-3-carbaldehyde N,N-dimethyl-2-oxoacetamide 2-methylpent-4-yn-2-ol 3-tert-butyl-4-hydroxybenzonitrile 4-bromo-2-tert-butylphenol 1,3-dibutoxypropan-2-ol methyl4-hydroxyquinoline-6-carboxylate methyl3-cyano-4-hydroxybenzoate 4-chloro-6-methoxyquinolin-7-ol 3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol 2-(2-aminothiazol-5-yl)ethanolhydrochloride (R)-ethyl2-chloropropanoate (S)-4-amino-5-(4,4-dimethylcyclohexylamino)-5-oxopentanoicacid (1s,4s)-4-hydroxycyclohexanecarboxylicacid (S)-2-(tetrahydrofuran-3-yloxy)aceticacid (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol (R)-4-(hydroxymethyl)oxazolidin-2-one (S)-4-(hydroxymethyl)oxazolidin-2-one 化工資訊 6月2日，記者從佛慈制藥股份有限公司獲悉，在日前召開的甘肅省地方習用藥材質量標準審核審定會議上，由佛慈制藥研究院承擔的甘肅省中藥材標準修訂順利通過專家組審定。
據了解，按照2020年版《甘肅省中藥材標準》修訂背景、甘肅習用藥材修訂工作進展情況及此次修訂工作下一步要求，佛慈制藥研究院從企業(yè)自身產品出發(fā)，承擔了人參須等五個地方藥材標準的修訂工作，在本次審定會中進行了匯報和答辯，與會專家對修訂方案和研究內容進行了認真討論，最終順利通過審定。至此，佛慈制藥承擔的全部五個地方藥材的標準修訂工作畫上了圓滿的句號，將在2020年版《甘肅省中藥材標準》中出版、實施和推廣。
佛慈制藥作為甘肅省中藥龍頭企業(yè)積極合作，深入調研，扎實開展修訂工作。通過中藥民族藥標準化研究，對挖掘和保護甘肅道地藥材資源、繼承和弘揚中醫(yī)藥傳統(tǒng)文化、帶動中醫(yī)藥產業(yè)科技創(chuàng)新、推動我省中醫(yī)藥產業(yè)發(fā)展、保障公眾用藥安全意義深遠，具有很大的社會和經濟效益。
